1,926 Ebola Cases and 702 Deaths: Could Oral Gummies Change Outbreak Response?

The ongoing Bundibugyo Ebola outbreak is testing the limits of traditional outbreak response. Intravenous drugs and injectable vaccines confronting a highly contagious pathogen in remote northeastern DRC are daunting. An oral antiviral that can be distributed without cold chain, administered by non-clinicians, and given to children as gummies could fundamentally alter containment dynamics. With no approved specific countermeasure for this strain, public health systems are watching NanoViricides’ NV-387 closely as a potential game-changer for health security in Africa and beyond.

NanoViricides announced on July 13, 2026, that it has received National Ethics Committee approval in the Democratic Republic of Congo (DRC) to begin a Phase II clinical trial for its antiviral candidate NV-387, formulated as oral gummies, for the treatment of Ebola virus disease caused by the Bundibugyo strain. The approval comes amid a rapidly expanding outbreak that, as of July 12, 2026, had reached 1,926 confirmed cases and 702 deaths across the northeastern provinces of Haut-Uele and Tshopo, according to the DRC’s public health institute. This marks a critical milestone, not only for the company but for global outbreak response, as there is currently no approved vaccine or treatment for this particular ebolavirus variant, which appears to be a newly introduced strain likely originating from an animal reservoir.

“

With no approved specific countermeasure for this strain, public health systems are watching NanoViricides’ NV-387 closely as a potential game-changer for health security in Africa and beyond.

The strategic significance of NV-387 lies in its oral formulation. In resource-limited settings like those affected by the current outbreak, an oral drug eliminates the need for cold chain logistics, sterile intravenous administration, and specialized healthcare personnel, dramatically simplifying distribution and compliance. NanoViricides had previously shipped NV-387 to the DRC for a planned Phase II trial against Mpox, meaning sufficient drug supply is already in-country. This logistical head start could enable rapid initiation of the Ebola trial once regulatory filings with the Congolese agency ACOREP are completed. The company has mobilized a trial team including a lead investigator and a local university, underscoring the operational readiness.

From a public health standpoint, the trial is a high-stakes gambit. The Bundibugyo ebolavirus is one of the rarer species of Ebola, historically associated with smaller outbreaks but carrying a significant mortality rate. The current outbreak’s severity and expansion into new provinces heighten the urgency. If NV-387 demonstrates efficacy, it could become the first oral treatment for Ebola, potentially transforming the standard of care not only for this outbreak but for future filovirus epidemics. The oral gummy format also raises questions about dosing accuracy, stability in tropical climates, and pediatric acceptance—factors that will be closely watched during the trial.

Market implications are notable. NanoViricides (NYSE American: NNVC) is a clinical-stage biotech with a market cap that often fluctuates on development milestones. The news of ethics approval positions the company as a leading player in the niche of pan-viral therapies, leveraging its nanoviricide platform that mimics host cell receptors to trap and neutralize viruses. The dual applicability of NV-387 against both Mpox and Ebola suggests a broad-spectrum potential that could open larger addressable markets. However, investors should temper expectations: Phase II trials are designed to assess dosing and safety signals, not definitive efficacy, and the path to regulatory approval remains uncertain. Moreover, the company has not yet filed the Clinical Trial Application, so the trial is not yet underway.